Clive Meanwell, MB, ChB, MD hons, is the Chief Executive Officer of The Medicines Company (NASDAQ – MDCO) which, among other products, developed Angiomax®, Cleviprex® and Kengreal® – used in acute cardiovascular care. The firm is developing inclisiran, a PCSK9 synthesis inhibitor harnessing RNA interference which is expected to phase III clinical trials shortly.
Dr. Meanwell is also Vice Chairman of BB Biotech, a Swiss investment corporation. Before founding The Medicines Company, Dr. Meanwell was a partner and senior managing director with MPM Capital in Cambridge, MA. Previously he held a range of leadership positions with Roche in Switzerland and in California. He trained in medicine at The University of Birmingham, UK where he also undertook a clinical research fellowship in oncology.